Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eplontersen versus placebo in transthyretin-mediated amyloid cardiomyopathy
MOH_2020-05-10_008924Phase 3Active, not recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Mar 2020
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in amyloidotic transthyretin cardiomyopathy (ATTR-CM) comparing ION-682884 with Placebo (2 arms). Started Mar 2020; status: active, not recruiting.
02
Drugs
eplontersen
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on MOH_2020-05-10_008924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-05-10_008924.